Want to see SVA full AI Analyst Report?
Sinovac Biotech (SVA) Ratios
Sinovac Biotech Ratios
SVA's free cash flow for Q1 2024 was $93.26M. For the 2024 fiscal year, SVA's free cash flow was decreased by $-52.75M and operating cash flow was $146.01M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 4.59 | ― | 10.31 | 11.11 | 6.18 |
| Quick Ratio | 4.53 | ― | 10.18 | 10.94 | 6.03 |
| Cash Ratio | 0.75 | ― | 1.11 | 3.92 | 4.81 |
| Solvency Ratio | 0.02 | ― | 0.03 | 0.19 | 2.98 |
| Operating Cash Flow Ratio | -0.33 | ― | 0.09 | -0.71 | 6.36 |
| Short-Term Operating Cash Flow Coverage | -2.19 | ― | 1.37 | -165.72 | 3279.76 |
| Net Current Asset Value | $ 4.83B | ― | $ 10.20B | $ 10.72B | $ 12.04B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.06 | ― | 0.02 | 0.01 | 0.01 |
| Debt-to-Equity Ratio | 0.11 | ― | 0.03 | 0.01 | 0.02 |
| Debt-to-Capital Ratio | 0.10 | ― | 0.03 | 0.01 | 0.02 |
| Long-Term Debt-to-Capital Ratio | 0.06 | ― | 0.02 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.95 | ― | 1.57 | 1.58 | 1.80 |
| Debt Service Coverage Ratio | -0.51 | ― | -1.42 | 41.59 | 1935.42 |
| Interest Coverage Ratio | -29.67 | ― | -241.91 | -368.72 | 6189.44 |
| Debt to Market Cap | 1.07 | ― | 0.39 | 0.03 | 0.03 |
| Interest Debt Per Share | 7.19 | ― | 3.02 | 0.76 | 1.49 |
| Net Debt to EBITDA | 3.46 | ― | 161.08 | -22.96 | -0.65 |
| Profitability Margins | |||||
| Gross Profit Margin | 67.87% | ― | 59.51% | 54.15% | 94.47% |
| EBIT Margin | -75.47% | ― | -33.63% | 1.78% | 90.66% |
| EBITDA Margin | -48.61% | ― | -1.34% | 12.27% | 91.11% |
| Operating Profit Margin | -75.47% | ― | -121.96% | -31.22% | 90.60% |
| Pretax Profit Margin | -67.90% | ― | -34.14% | 1.69% | 90.65% |
| Net Profit Margin | -15.46% | ― | -22.29% | 7.63% | 43.70% |
| Continuous Operations Profit Margin | -51.51% | ― | -57.63% | 5.90% | 74.63% |
| Net Income Per EBT | 22.77% | ― | 65.29% | 451.17% | 48.21% |
| EBT Per EBIT | 89.97% | ― | 27.99% | -5.42% | 100.06% |
| Return on Assets (ROA) | -0.69% | ― | -0.73% | 0.81% | 50.56% |
| Return on Equity (ROE) | -1.34% | ― | -1.15% | 1.28% | 90.78% |
| Return on Capital Employed (ROCE) | -4.11% | ― | -4.37% | -3.58% | 122.45% |
| Return on Invested Capital (ROIC) | -3.02% | ― | -4.34% | -3.58% | 100.70% |
| Return on Tangible Assets | -0.70% | ― | -0.73% | 0.81% | 50.68% |
| Earnings Yield | -12.84% | ― | -15.50% | 17.69% | 1317.80% |
| Efficiency Ratios | |||||
| Receivables Turnover | 1.23 | ― | 0.99 | 2.45 | 20.34 |
| Payables Turnover | 7.64 | ― | 10.50 | 34.52 | 18.30 |
| Inventory Turnover | 1.32 | ― | 1.30 | 3.79 | 2.86 |
| Fixed Asset Turnover | 0.54 | ― | 0.43 | 1.27 | 17.87 |
| Asset Turnover | 0.04 | ― | 0.03 | 0.11 | 1.16 |
| Working Capital Turnover Ratio | 0.05 | ― | 0.04 | 0.13 | 2.90 |
| Cash Conversion Cycle | 525.82 | ― | 613.49 | 234.83 | 125.83 |
| Days of Sales Outstanding | 296.04 | ― | 367.00 | 149.03 | 17.94 |
| Days of Inventory Outstanding | 277.53 | ― | 281.26 | 96.37 | 127.83 |
| Days of Payables Outstanding | 47.75 | ― | 34.77 | 10.57 | 19.94 |
| Operating Cycle | 573.58 | ― | 648.26 | 245.40 | 145.77 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -7.10 | ― | 1.04 | -7.75 | 154.59 |
| Free Cash Flow Per Share | -7.78 | ― | -0.42 | -11.80 | 147.34 |
| Dividend Paid and CapEx Coverage Ratio | -0.14 | ― | 0.22 | -1.16 | 5.91 |
| Capital Expenditure Coverage Ratio | -10.44 | ― | 0.71 | -1.91 | 21.32 |
| Operating Cash Flow Coverage Ratio | -1.01 | ― | 0.35 | -10.32 | 105.95 |
| Operating Cash Flow to Sales Ratio | -1.32 | ― | 0.23 | -0.52 | 0.79 |
| Free Cash Flow Yield | -120.32% | ― | -6.47% | -182.38% | 2277.28% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -7.80 | ― | -6.10 | 5.99 | 0.08 |
| Price-to-Sales (P/S) Ratio | 1.20 | ― | 1.44 | 0.43 | 0.03 |
| Price-to-Book (P/B) Ratio | 0.10 | ― | 0.07 | 0.07 | 0.07 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.83 | ― | -15.46 | -0.55 | 0.04 |
| Price-to-Operating Cash Flow Ratio | -0.91 | ― | 6.20 | -0.84 | 0.04 |
| Price-to-Earnings Growth (PEG) Ratio | 0.05 | ― | 0.03 | -0.06 | 0.00 |
| Enterprise Value Multiple | 0.98 | ― | 54.19 | -19.44 | -0.61 |
| Enterprise Value | -184.52M | ― | -326.69M | -3.56B | -10.82B |
| EV to EBITDA | 0.98 | ― | 54.19 | -19.44 | -0.61 |
| EV to Sales | -0.48 | ― | -0.73 | -2.38 | -0.56 |
| EV to Free Cash Flow | 0.33 | ― | 7.84 | 3.03 | -0.74 |
| EV to Operating Cash Flow | 0.36 | ― | -3.14 | 4.62 | -0.70 |
| Tangible Book Value Per Share | 87.83 | ― | 120.62 | 126.96 | 139.31 |
| Shareholders’ Equity Per Share | 61.77 | ― | 87.44 | 89.66 | 93.92 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.24 | ― | -0.69 | -2.49 | 0.18 |
| Revenue Per Share | 5.37 | ― | 4.50 | 15.00 | 195.09 |
| Net Income Per Share | -0.83 | ― | -1.00 | 1.14 | 85.26 |
| Tax Burden | 0.23 | ― | 0.65 | 4.51 | 0.48 |
| Interest Burden | 0.90 | ― | 1.01 | 0.95 | 1.00 |
| Research & Development to Revenue | 0.56 | ― | 0.77 | 0.30 | 0.01 |
| SG&A to Revenue | 0.87 | ― | 1.04 | 0.55 | 0.03 |
| Stock-Based Compensation to Revenue | 0.00 | ― | 0.00 | 0.00 | 0.00 |
| Income Quality | 8.55 | ― | -0.40 | -8.75 | 1.06 |
Currency in USD
